TWI916375B - 軸突損傷之預防 - Google Patents

軸突損傷之預防

Info

Publication number
TWI916375B
TWI916375B TW110123285A TW110123285A TWI916375B TW I916375 B TWI916375 B TW I916375B TW 110123285 A TW110123285 A TW 110123285A TW 110123285 A TW110123285 A TW 110123285A TW I916375 B TWI916375 B TW I916375B
Authority
TW
Taiwan
Prior art keywords
patient
nfl
tau
csf
antibody
Prior art date
Application number
TW110123285A
Other languages
English (en)
Chinese (zh)
Other versions
TW202216188A (zh
Inventor
凱特 譚
克雷格 謝林
約翰 R 希姆斯
傑弗瑞 Ｌ 達格
Original Assignee
英商梅迪繆思有限公司
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商梅迪繆思有限公司, 美商美國禮來大藥廠 filed Critical 英商梅迪繆思有限公司
Publication of TW202216188A publication Critical patent/TW202216188A/zh
Application granted granted Critical
Publication of TWI916375B publication Critical patent/TWI916375B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW110123285A 2020-06-25 2021-06-25 軸突損傷之預防 TWI916375B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043872P 2020-06-25 2020-06-25
US63/043,872 2020-06-25

Publications (2)

Publication Number Publication Date
TW202216188A TW202216188A (zh) 2022-05-01
TWI916375B true TWI916375B (zh) 2026-03-01

Family

ID=76662499

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110123285A TWI916375B (zh) 2020-06-25 2021-06-25 軸突損傷之預防
TW115103567A TW202619748A (zh) 2020-06-25 2021-06-25 軸突損傷之預防

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW115103567A TW202619748A (zh) 2020-06-25 2021-06-25 軸突損傷之預防

Country Status (11)

Country Link
US (1) US20230287092A1 (enExample)
EP (1) EP4171742A1 (enExample)
JP (1) JP2023531069A (enExample)
KR (1) KR20230026490A (enExample)
CN (1) CN116547299A (enExample)
AU (1) AU2021295605A1 (enExample)
BR (1) BR112022026359A2 (enExample)
CA (1) CA3187785A1 (enExample)
IL (1) IL299215A (enExample)
TW (2) TWI916375B (enExample)
WO (1) WO2021260193A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
WO2024015951A2 (en) * 2022-07-15 2024-01-18 Seq Biomarque, Llc Methods and materials for identifying biomarkers and/or pathways associated with alzheimer's disease
CN117624357B (zh) * 2024-01-26 2024-03-22 南京诺唯赞医疗科技有限公司 p-Tau 217特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014060444A1 (en) 2012-10-15 2014-04-24 Medimmune Limited Antibodies to amyloid beta

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US151A (en) 1837-03-25 Spring-saddle
US5654A (en) 1848-06-27 Door-spring
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
ES2276405T3 (es) 1995-06-02 2007-06-16 Gilead Sciences, Inc. Ligandos de oligonucleotidos de alta afinidad a pdgf.
US8481277B2 (en) * 2007-08-21 2013-07-09 Washington University Alzheimer's diagnosis
US9958460B2 (en) * 2013-10-24 2018-05-01 Nanosomix, Inc. Biomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders
SI3769781T1 (sl) 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
AR107893A1 (es) * 2016-03-15 2018-06-28 Astrazeneca Ab TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
JP7177702B2 (ja) * 2016-05-06 2022-11-24 ナノソミックス・インコーポレイテッド アルツハイマー病および他の神経変性障害のシナプスタンパク質バイオマーカーおよび鑑別診断
JP6949102B2 (ja) * 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
US12117456B2 (en) * 2016-11-10 2024-10-15 Brain Biomarker Solutions In Gothenburg Ab Methods for detecting an individual as being at risk of developing a neurodegenerative disease
CN113853214A (zh) * 2019-05-21 2021-12-28 Ac免疫有限公司 抗Aβ疫苗治疗

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014060444A1 (en) 2012-10-15 2014-04-24 Medimmune Limited Antibodies to amyloid beta

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Soares H., et al., "O3-09-05: PLASMA TAU AND NEUROFILAMENT LIGHT CHAIN AS A PROGNOSTIC BIOMARKER OF DISEASE PROGRESSION IN EARLY ALZHEIMER’S DISEASE", Podium Presentations, Volume14, Issue7S_Part_19, July 2018, Pages P1038-P1039.

Also Published As

Publication number Publication date
TW202619748A (zh) 2026-05-16
BR112022026359A2 (pt) 2023-01-17
KR20230026490A (ko) 2023-02-24
TW202216188A (zh) 2022-05-01
US20230287092A1 (en) 2023-09-14
AU2021295605A1 (en) 2023-02-16
IL299215A (en) 2023-02-01
CN116547299A (zh) 2023-08-04
CA3187785A1 (en) 2021-12-30
EP4171742A1 (en) 2023-05-03
WO2021260193A1 (en) 2021-12-30
JP2023531069A (ja) 2023-07-20

Similar Documents

Publication Publication Date Title
CN113597431B (zh) 识别Tau的抗体
JP6446443B2 (ja) タウオパチーの処置方法
BR112020018868A2 (pt) métodos baseados em anticorpo para detectar e tratar doença de alzheimer
US11028157B2 (en) Binding molecules that specifically bind to tau
TW202100550A (zh) 識別ｔａｕ之抗體
CA2974993A1 (en) Anti-transthyretin antibodies
CN117820467A (zh) 抗tau抗体和使用方法
TW202216188A (zh) 軸突損傷之預防
CN107074937A (zh) 人源抗亨廷顿蛋白（htt）抗体及其用途
US20240059766A1 (en) Tau binding compounds
JP2021508366A (ja) 気分障害の治療及び診断のための抗−配列類似性１９を持つファミリー、メンバーａ５抗体の用途
US20240150451A1 (en) Anti-tau antibodies and uses thereof
KR20220076658A (ko) Aimp2 및/또는 aimp2 응집체에 특이적으로 결합하는 항체
US11274147B2 (en) Binding molecules that specifically bind to tau
BR122025021109A2 (pt) Uso de um elemento de ligação que se liga seletivamente ao peptídeo beta amiloide 1-42 humano, método para avaliar a eficácia do uso, método para identificar um paciente como adequado para o uso, e kit
JP2018508193A (ja) メディンを認識する抗体
EA047298B1 (ru) Антитела к phf-тау и их применение
EP4642798A1 (en) Compositions and methods for treating alpha-synucleinopathies
EA047155B1 (ru) Антитела, распознающие тау